Biotech stocks have benefited from the recent decline in risk perceptions. The iShares Biotech Fund (IBB) is up 3.6 percent today and has added 8 percent since March 20, compared to a 2.9 percent gain for the S&P 500 (.SPX). Today, a number of individual biotech names saw unusual volume in the options market. The list includes Intermune (ITMN), Pozen Pharmaceuticals (POZN), Amylin Pharmaceuticals (AMLN), OSI Pharmaceuticals (OSIP), and Forest Labs (FRX).